QE JCI, ES

Form 1449 (Modified)

Information Disclosure Statement By Applicant

(Use Several Sheets if Necessary)

Atty Docket No. CYTOP002D1 Application No.: 10/082,036

Applicant:

Kathleen A. Elias Filing Date

February 20, 2002

Group 1631

**U.S. Patent Documents** 

					Sub-	Filing
No.	Patent No.	Date	Patentee	Class	class	Date
1	4,818,710	04/04/1989	Sutherland et al.			
2	4,922,092	05/01/1990	Rushbrooke et al.	_	RFC	FIVE
3	5,287,272	02/15/1994	Rutenberg et al.			
4	5,526,258	06/11/1996	Bacus		- AUG	2 8 2002
5	5,733,721	03/31/1998	Hemstreet, III et al.		ECH CENT	ED 4005/200
6	5,893,095	04/06/1999	Jain et al.		FOU OFIA	<del>LH 1600/29</del> 0
7	6,083,763	07/04/2000	Balch			
8	6,345,115	02/05/2002	Ramm et al.		_	
9	RE 34,214	04/06/1993	Carlsson et al.			
	1 2 3 4 5 6 7 8	1 4,818,710 2 4,922,092 3 5,287,272 4 5,526,258 5 5,733,721 6 5,893,095 7 6,083,763 8 6,345,115	1 4,818,710 04/04/1989 2 4,922,092 05/01/1990 3 5,287,272 02/15/1994 4 5,526,258 06/11/1996 5 5,733,721 03/31/1998 6 5,893,095 04/06/1999 7 6,083,763 07/04/2000 8 6,345,115 02/05/2002	1 4,818,710 04/04/1989 Sutherland et al. 2 4,922,092 05/01/1990 Rushbrooke et al. 3 5,287,272 02/15/1994 Rutenberg et al. 4 5,526,258 06/11/1996 Bacus 5 5,733,721 03/31/1998 Hemstreet, III et al. 6 5,893,095 04/06/1999 Jain et al. 7 6,083,763 07/04/2000 Balch 8 6,345,115 02/05/2002 Ramm et al.	1       4,818,710       04/04/1989       Sutherland et al.       —         2       4,922,092       05/01/1990       Rushbrooke et al.       —         3       5,287,272       02/15/1994       Rutenberg et al.       —         4       5,526,258       06/11/1996       Bacus       —         5       5,733,721       03/31/1998       Hemstreet, III et al.       —         6       5,893,095       04/06/1999       Jain et al.       —         7       6,083,763       07/04/2000       Balch       —         8       6,345,115       02/05/2002       Ramm et al.       —	No.         Patent No.         Date         Patentee         Class         class           1         4,818,710         04/04/1989         Sutherland et al.         —           2         4,922,092         05/01/1990         Rushbrooke et al.         —           3         5,287,272         02/15/1994         Rutenberg et al.         —           4         5,526,258         06/11/1996         Bacus         —         AUG           5         5,733,721         03/31/1998         Hemstreet, III et al.         IECH CENT           6         5,893,095         04/06/1999         Jain et al.         —           7         6,083,763         07/04/2000         Balch         —           8         6,345,115         02/05/2002         Ramm et al.         —

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
125	10	WO 9522749	24 AUG 95	PCT/WIPO	T		Y	
1/2/3	11	EP 0317139	24 MAY 89	EPO			Y	
V								

### Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
12/3	12	Sunblad et al., "The use of image analysis and automation for measuring mitotic index in apical confier meristems", © Oxford University Press 1998, Journal of Experimental Botany, Vol. 49, No. 327, pp. 1749-56
V		

Examiner		Date Considered	
Ì	loss Bruse	1400 Teles 2003	

Examiner / Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY OF PAPERS OF GINALLY FILED

gym 1449 (Modified)

Atty Docket No. CYTOP002D1

Application No.:

**Information Disclosure** 

Applicant:

10/082,036

**Statement By Applicant** 

Kathleen A. ELIAS Filing Date

(Use Several Sheets if Necessary)

February 20, 2002

Group 1631

**U.S. Patent Documents** 

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	class	Date
1865	A	5,162,990	Nov 1992	Odeyale et al.			
700	В						
	G						
	Н						
	I						

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	slation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
1953	J	WO 98/52018	Nov 1998	PCT				
	K							
	L							
	M							
	N							

### **Other Documents**

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
n A	0	ANCIN, Hakan et al., "Advances in Automated 3-D Image Analysis of Cell
1	1	Populations Imaged by Confocal Microscopy", 1996, Cytometry, Vol. 25, pp.
		221-234.
NB	P	MALPICA, Norberto et al., "Applying Watershed Algorithms to the
( Ja)		Segmentation of Clustered Nuclei", 1997, Cytometry, Vol. 28, pp. 289-297.
2/5	Q	NILSSON, Björn et al., "Segmentation of Dense Leukocyte Clusters", 2001,
		IEEE Workshop on Mathematical Methods in Biomedical Image Analysis,
7		Kauai, Hawaii, pp. 221-227.
Examiner		O Date Considered
101	15.	June 140cldw 2007

Examined: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

corm 1449 (Modified)

Information Disclosure Statement By Applicant

(Use Several Sheets if Necessary)

Atty Docket No. CYTOP002D1

Applicant:

Elias Filing Date

February 20, 2002

Application No.:

10/082,036

Group 1631

**U.S. Patent Documents** 

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	class	Date
125	1	6,146,830	11/14/2000	Friend et al.			
1865	2	6,222,093	04/24/2001	Marton et al.			ĘŲ.
2						CELA	
					Q\		100s
						4.3	
						401	0 1600/2000
					[	1/12	
						ECHCENI	
						10	
							1

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	slation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
125	. 3	WO 94/11841	05/26/1994	PCT			X	
MBB	' 4	WO 00/70528 A2	11/23/2000	WIPO			X	
7								
								1

**Other Documents** 

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	-5-	Cseke, I., "A Fast Segmentation Scheme for White Blood Cell Images" (1992)
		IEEE, pp. 530-533 no copy provided in 09/14/12-1
	6	Serbouti, S., et al., "Image Segmentation and Classification Methods to Detect
		Leukemias", (1991) Annual Int'l Conf. of IEEE Eng. In Medicine & Biology
	ŀ	Soc., Vol. 13, No. 1, pp. 0260-0261 no copy provided in of 74172)
Examiner		Date Considered
ļ	Note	5. (Brusea 14 colde 2003
Eveniner	Initial	gitation considered. Draw line through citation if not in conformance and

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**Information Disclosure** Statement By Applicant

Atty Docket No. CYTOP002D1 Applicant: Kathleen A. Elias Filing Date February 20, 2002

(Use Several Sheets if Necessary)

Application No.: 10/082,036

Application No.: 10/082,036

Application No.: 10/082,036 **U.S. Patent Documents** Examiner Initial No. Patent No. Date Patentee Class 5,326,691 07/05/94 Hozier Schroeder et al. В 5,355,215 10/11/94

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
JEG	C3	93/21511	28.10.93	PCT				
10	Dyo	94/11841	26.05.94	PCT				
183	E,	96/09605	28.03.96	PCT				
BB	F.30	97/43732	20.11.97	PCT				
Ok C	G <sub>4</sub>	99/05323	04.02.99	PCT		_		
	H <sup>4</sup> <sub>D</sub>	00/70528	23/11/00	PCT			[	

#### Other Documents

		Omer Docum	rents				
Examiner	}		•				
Initial	No.	Author, Title, Date, Place (e.g	Journal) of Publication				
MA	I	Adams et al., "Cell patterning o	n glass and polymeric substrates" US Patent				
		Application No. 60/138,119, file	ed June 7, 1999				
TO ,	J		cationof Spatically Controlled Miniaturized				
1 12/3		Organ Systems from Stem Cells	s", US Patent Application No. 60/127,339,				
<b>√</b>	l	filed April 1, 1999					
	K,	Hofland et al., "Role of Tumor	- Derived Fibroblasts in the Growth of				
MA	-	Primary Cultures of Human Bre	east-Cancel Cells: Effects of Epidermal				
1 150		Frowth Factor and the Somatostatin Analogue Octreotide", 1995, Int. J.					
		Cancer: 60, 93-99.					
	L.		L-10) inhibition of primary human prostate				
100	1	cell-induced angiogenesis: IL-1	0 stimulation of tissue inhibitor of				
1 1/2	}	metalloproteinase-1 and inhibiti	on of matrix metalloproteinase (MMP)				
$\langle \rangle$		2/MMP-9 Secretion", January 1	999, Clinical Cancer Research, vol. 5 189-196.				
	M ,	Takayama et al., "Patterning cel	lls and their environments using multiple				
1 125	}	laminar fluid flows in capillary	networks", May 1999, Proc. Natl., Acad. Sci.				
72	USA, vol. 96, pp. 5545-5548.						
Examiner	Λ .	n () Da	ite Considered				
1	100	S. Busch	14 October 2003				

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			2 =
F rm 1449 (Modified)	Atty Docket No.	Application No.:	
· ·	CYTOP002D1	NEW	S
Information Disclosure	Applicant:		⇒ <b>2 = 2</b>
Statement By Applicant	Kathleen A. Elias		
	Filing Date	Group	1637
(Use Several Sheets if Necessary)	HEREWITH	UNASSIGNED	Ť  <b>=</b>

# **U.S. Patent Documents**

Examiner   No.   Patent No.   Date   Patentee   Class   Class   Date	<u></u>	,	,	U.S. I atch	t Documents	<del></del>		,
A1 6,008,010 12/28/99 Greenberger et al.  A2 5,989,835 11/23/99 Dunlay et al.  A3 60/120,801 02/19/99 Wang et al.  A4 60/142,646 07/06/99 Boyce et al.  A5 60/142,375 07/06/99 Boyce et al.  A6 60/108,291 11/13/98 Boyce et al.  A7 60/110,643 12/01/98 Smith  A8 60/140,240 06/21/99 Dunlay et al.  A8 60/140,240 06/21/99 Dunlay et al.  A9 5,655,028 08/05/97 Soll  A10 5,976,825 11/2/99 Hochman  A12 5,919,646 07/06/99 Okun et al.  A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  A16 5,991,028 11/23/99 McNamara et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 A20 5,790,710 08/04/98 Price et al.  A21 A22 5,932,872 08/13/99 Price et al.  A22 5,932,872 08/13/99 Price et al.  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.	Examiner			_			Sub-	Filing
A2 5,989,835 11/23/99 Dunlay et al.  A3 60/120,801 02/19/99 Wang et al.  A4 60/142,646 07/06/99 Boyce et al.  A5 60/142,375 07/06/99 Boyce et al.  A6 60/108,291 11/13/98 Boyce et al.  A7 60/110,643 12/01/98 Smith  A8 60/140,240 06/21/99 Dunlay et al.  A9 5,655,028 08/05/97 Soll  A10 5,976,825 11/2/99 Hochman  A12 5,919,646 07/06/99 Okun et al.  A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  A15 A16 5,991,028 11/23/99 Cabib et al.  A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,932,872 08/13/99 Price et al.  A22 5,932,872 08/13/99 Price et al.  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.	Initial				I	Class	class	Date
A3 60/120,801 02/19/99 Wang et al.  A4 60/142,646 07/06/99 Boyce et al.  A5 60/142,375 07/06/99 Boyce et al.  A6 60/108,291 11/13/98 Boyce et al.  A7 60/110,643 12/01/98 Smith  A8 60/140,240 06/21/99 Dunlay et al.  A9 5,655,028 08/05/97 Soll  A10 5,976,825 11/2/99 Hochman  D15 A11 5,804,436 09/08/98 Okun et al.  D2 A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  D3 A17 6,007,996 12/28/99 McNamara et al.  D4 A18 5,548,661 08/20/96 Price et al.  D4 A19 5,790,692 08/04/98 Price et al.  D4 A20 5,790,710 08/04/98 Price et al.  D4 A21 5,856,665 01/05/99 Price et al.  D4 A22 5,932,872 08/13/99 Price et al.  D4 A23 5,995,143 11/30/99 Price et al.  D4 A24 5,776,748 06/07/98 Singhyi et al.  D4 A25 4,959,301 09/25/90 Weaver et al.	132	1	l	1				
A4 60/142,646 07/06/99 Boyce et al.  A5 60/142,375 07/06/99 Boyce et al.  A6 60/108,291 11/13/98 Boyce et al.  A7 60/110,643 12/01/98 Smith  A8 60/140,240 06/21/99 Dunlay et al.  A9 5,655,028 08/05/97 Soll  A10 5,976,825 11/2/99 Hochman  B15 A11 5,804,436 09/08/98 Okun et al.  A12 5,919,646 07/06/99 Okun et al.  A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,950,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price et al.  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhyi et al.  A25 4,959,301 09/25/90 Weaver et al.	125							
A5 60/142,375 07/06/99 Boyce et al.  A6 60/108,291 11/13/98 Boyce et al.  A7 60/110,643 12/01/98 Smith  A8 60/140,240 06/21/99 Dunlay et al.  A9 5,655,028 08/05/97 Soll  A10 5,976,825 11/2/99 Hochman  A1 5,804,436 09/08/98 Okun et al.  A12 5,919,646 07/06/99 Okun et al.  A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A20 5,995,143 11/30/99 Price et al.  A21 5,932,872 08/13/99 Price et al.  A22 5,932,872 08/13/99 Price et al.  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.	089	A3		l				
A6 60/108,291 11/13/98 Beyce et al. no Copy provide to 1,5 08/2017 2  A7 60/110,643 12/01/98 Smith  A8 60/140,240 06/21/99 Dunlay et al.  A9 5,655,028 08/05/97 Soll  A10 5,976,825 11/2/99 Hochman  C1 A11 5,804,436 09/08/98 Okun et al.  A12 5,919,646 07/06/99 Okun et al.  A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A20 5,995,143 11/30/99 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A24 5,776,748 06/07/98 Singhvi et al.  A25 A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	NEC	A4	60/142,646	07/06/99	Boyce et al.			
A6 60/108,291 11/13/98 Boyce et al. no Copy Gravide Copy	BB	A5	60/142,375	07/06/99	Boyce et al.			
A7 60/110,643 12/01/98 Smith  A8 60/140,240 06/21/99 Dunlay et al.  A9 5,655,028 08/05/97 Soll  A10 5,976,825 11/2/99 Hochman  A11 5,804,436 09/08/98 Okun et al.  A12 5,919,646 07/06/99 Okun et al.  A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.		-A6	60/108,291	11/13/98	Boyce et al.	nocory	provide	1 09/74/172
A9   5,655,028   08/05/97   Soll     A10   5,976,825   11/2/99   Hochman     A11   5,804,436   09/08/98   Okun et al.     A12   5,919,646   07/06/99   Okun et al.     A13   6,103,479   08/15/00   Taylor     A14   4,965,725   10/23/90   Rutenberg     A15   5,741,648   04/21/98   Hemstreet et al.     A16   5,991,028   11/23/99   Cabib et al.     A17   6,007,996   12/28/99   McNamara et al.     A18   5,548,661   08/20/96   Price et al.     A19   5,790,692   08/04/98   Price et al.     A20   5,790,710   08/04/98   Price et al.     A21   5,856,665   01/05/99   Price et al.     A22   5,932,872   08/13/99   Price et al.     A23   5,995,143   11/30/99   Price et al.     A24   5,776,748   06/07/98   Singhvi et al.     A26   5,962,520   10/05/99   Gavin et al.     A26   5,962,520   10/05/99   Gavin et al.     A26   5,962,520   10/05/99   Gavin et al.	185	A7	60/110,643	12/01/98	Smith			**
A10 5,976,825 11/2/99 Hochman  [1] A11 5,804,436 09/08/98 Okun et al.  [2] A12 5,919,646 07/06/99 Okun et al.  [3] A13 6,103,479 08/15/00 Taylor  [4] A14 4,965,725 10/23/90 Rutenberg  [5] A15 5,741,648 04/21/98 Hemstreet et al.  [6] A16 5,991,028 11/23/99 Cabib et al.  [7] A17 6,007,996 12/28/99 McNamara et al.  [8] A18 5,548,661 08/20/96 Price et al.  [8] A19 5,790,692 08/04/98 Price et al.  [9] A20 5,790,710 08/04/98 Price et al.  [9] A21 5,856,665 01/05/99 Price et al.  [9] A22 5,932,872 08/13/99 Price  [9] A23 5,995,143 11/30/99 Price et al.  [9] A24 5,776,748 06/07/98 Singhvi et al.  [9] A25 4,959,301 09/25/90 Weaver et al.	VIC.	A8	60/140,240	06/21/99	Dunlay et al.			
A10   5,976,825   11/2/99   Hochman	BB	A9	5,655,028	08/05/97	Soll			
A12 5,919,646 07/06/99 Okun et al.  WC A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  WC A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 A26 5,962,520 10/05/99 Gavin et al.		A10	5,976,825	11/2/99	Hochman			
A12 5,919,646 07/06/99 Okun et al.  (C) A13 6,103,479 08/15/00 Taylor  A14 4,965,725 10/23/90 Rutenberg  (C) A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  (A17 6,007,996 12/28/99 McNamara et al.  (A18 5,548,661 08/20/96 Price et al.  (A19 5,790,692 08/04/98 Price et al.  (A20 5,790,710 08/04/98 Price et al.  (A21 5,856,665 01/05/99 Price et al.  (A22 5,932,872 08/13/99 Price  (A23 5,995,143 11/30/99 Price et al.  (A24 5,776,748 06/07/98 Singhvi et al.  (A25 4,959,301 09/25/90 Weaver et al.  (A26 5,962,520 10/05/99 Gavin et al.	123	A11	5,804,436	09/08/98	Okun et al.			
A14 4,965,725 10/23/90 Rutenberg  A15 5,741,648 04/21/98 Hemstreet et al.  A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 A26 5,962,520 10/05/99 Gavin et al.	1035	A12	5,919,646	07/06/99	Okun et al.			
A14   4,965,725   10/23/90   Rutenberg     A15   5,741,648   04/21/98   Hemstreet et al.     A16   5,991,028   11/23/99   Cabib et al.     A17   6,007,996   12/28/99   McNamara et al.     A18   5,548,661   08/20/96   Price et al.     A19   5,790,692   08/04/98   Price et al.     A20   5,790,710   08/04/98   Price et al.     A21   5,856,665   01/05/99   Price et al.     A22   5,932,872   08/13/99   Price     A23   5,995,143   11/30/99   Price et al.     A24   5,776,748   06/07/98   Singhvi et al.     A25   4,959,301   09/25/90   Weaver et al.     A26   5,962,520   10/05/99   Gavin et al.	2 1805	A13	6,103,479	08/15/00	Taylor			
A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	VIS	A14	4,965,725	10/23/90				
A16 5,991,028 11/23/99 Cabib et al.  A17 6,007,996 12/28/99 McNamara et al.  A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	2 80	A15	5,741,648	04/21/98	Hemstreet et al.			
A18 5,548,661 08/20/96 Price et al.  A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	VB3	A16	5,991,028	11/23/99	Cabib et al.			
A19 5,790,692 08/04/98 Price et al.  A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	JBB	A17	6,007,996	12/28/99	McNamara et al.			
A20 5,790,710 08/04/98 Price et al.  A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	3800	A18	5,548,661	08/20/96	Price et al.			
A21 5,856,665 01/05/99 Price et al.  A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	123	A19	5,790,692	08/04/98	Price et al.			
A22 5,932,872 08/13/99 Price  A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	Yes	A20	5,790,710	08/04/98	Price et al.			
A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	1 23	A21	5,856,665	01/05/99	Price et al.			
A23 5,995,143 11/30/99 Price et al.  A24 5,776,748 06/07/98 Singhvi et al.  A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	1 123	A22	5,932,872	08/13/99	Price			
A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	12/13	A23		11/30/99	Price et al.			
A25 4,959,301 09/25/90 Weaver et al.  A26 5,962,520 10/05/99 Gavin et al.	BC	A24		<u> </u>	Singhvi et al.	<b> </b>		
A26 5,962,520 10/05/99 Gavin et al.	VEG	A25	4,959,301	09/25/90				
	RB			<u> </u>	<del></del>			
	MAIS	A27		12/28/99	McNamara			
	7	<del></del>	<del></del>			J	L	

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	slation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
85	B1	WO 99/39184	08/05/99	PCT			X	
1/3/5	B2	WO 00/29984	05/25/00	PCT			X	
135	В3	WO 98/45704	10/15/98	PCT	1 =		X	

Pg. 1 of 4

JAB Briesa 148ctithe 2003

Form 1449 (Modified)	Atty Docket No.	Application No.:
	CYTOP002D1	NEW
Information Disclosure	Applicant:	
Statement By Applicant	Kathleen A. Elias	
	Filing Date	Group
(Use Several Sheets if Necessary)	HEREWITH	UNASSIGNED

185	B4	WO 99/17116	04/08/99	PCT			X	
V KB	<b>B</b> 5	WO 99/54494	10/28/99	PCT			X	
125	<b>B</b> 6	WO 98/05959	02/12/98	PCT			X	
1933	<b>B</b> 7	WO 00/33250	06/08/00	PCT			X	
12/5	B8	WO 00/03246	01/20/00	PCT	-		X	
1865	B9	WO 00/17624	03/30/00	PCT			X	
12/3	B10	WO 00/17643	03/30/00	PCT	•		X	
V)83	B11	WO 00/50872	08/31/00	PCT			X	
VCC)	B12	WO 00/60356	10/12/00	PCT		_	X	
SEB	B13	WO 97/45730	12/04/97	PCT			X	
K/C	B14	WO 98/38490	09/03/98	PCT	•	-	X	
PB	B15	WO 97/20198	06/05/97	PCT			X	
180	B16	WO 98/44333	10/08/98	PCT			X	
DED	B17	WO 99/44062	09/02/99	PCT			X	
3/2	B18	EP 0468705	01/29/92	EP			X	
133	B19	EP0902394	03/17/99	EP			X	
1815	B20	WO 00/06774	02/10/00	PCT			X	
7835	B21	WO 00/17808	03/30/00	PCT			X	
VIBB	B22	WO 00/26408	05/11/00	PCT			X	
<b>L</b> C	B23	WO 00/31534	06/02/00	PCT	_		X	
UKS	B24	WO 95/10036	04/13/95	PCT	-		X	
KB	B25	WO 99/67739	12/29/99	PCT		-	X	
URJ)	B26	WO 87/02802	05/07/87	PCT	-		X	
123	B27	WO 99/08091	02/18/99	PCT			X	
( BC)	B28	WO 00/49540	08/24/00	PCT			X	
1815	B29	WO 00/43820	07/27/00	PCT		_	X	
183	B30	WO 96/01438	01/18/96	PCT			X	
12/2	B31	WO 98/35256	08/13/98	PCT		$\overline{}$	X	
V 10(5	B32	WO 97/40055	10/30/97	PCT			X	
903	B33	WO 99/39184	08/05/99	PCT	7		X	
025	B34	EP0902394A1	03/17/99	EP	•		X	
< 1 ···								

J.B. Bruses 140ctile 2003

Form 1449 (Modified)	Atty Docket No. CYTOP002D1	Application No.: NEW
Information Disclosure	Applicant:	
Statement By Applicant	Kathleen A. Elias Filing Date	Group
(Use Several Sheets if Necessary)	HEREWITH	UNASSIGNED

# Other Documents

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
10/15	C1	Printout from Q3DM Website (www,Q3DM.com), printed on March 1, 2001,
- IN		30 Pages.
	C2	Montironi R., et al., "Computed Cell Cycle and DNA Histogram Analyses in
16/2	-	Image Cytometry in Breast Cancer", Journal of Clinical Pathology, GB,
7	1	London, Vol. 46, No. 9, September 1993, Pages 795-800.
	C3	Giuliano K.A., et al., "Fluorescent-Protein Biosensors: New Tools for Drug
W/3	}	Discovery", Trends in Biotechnology, GB, Elsevier Publications, Cambridge,
	}	Vol. 16, No. 3, March 1998, Pages 135-140.
14.0	C4	Printout from Automated Cell Website (www.automatedcell.com) printed on
180	Į .	March 9, 2001, 24 Pages.
	C5	Ravi Kapur, et al., "Design and Fabrication of Spatially Controlled
1 1412	i	Miniaturized Organ Systems From Stem Cells", U.S. Provisional Patent
100	}	Application No.: 60/127,339, Filed April 1, 1999, 21 Pages.
100-	C6	Giuliano et al., "High-Content Screening: A New Approach to Easing Key
XII		Bottlenecks in the Drug Discovery Process", J. Biomolecular Screening, 2(4):
\ <u>\</u>	<u> </u>	249 (1997).
	C7	Pauwels et al., "Determination of the Mechanism of Action of Anticancer
10M		Drugs by Means of the Computer- Assisted Microscope Image Analysis of
180	1	Feulgen-Stained Nuclei", <u>J. Pharmacological and Toxicological Methods</u> 37:
	ł	105-115 (1997).
-0	C8	Pauwels et al., "Monitoring Of Chemotherapy-Induced Morphonuclear
1 /2/2		Modifications By Means Of Digital Cell-Image
		Analysis", I. Cancer Res. Clin. Oncol., 119: 533-540 (1993).
	C9	Pauwels et al., "In Vitro Digital Cell Image Analysis of Morphonuclear
1003		Modifications Induced by Natural DNA- Interacting Anticancer Drugs in
1427		Three Neoplastic Cell Lines", Meth. Find. Exp. Clin. Pharmacol., 17(3): 151-
"		161 (1995).

JK. Buser 140 ctithe 2003

Form 1449 (Modified)	Atty Docket No. CYTOP002D1	Application No.: NEW
Information Disclosure Statement By Applicant	Applicant: Kathleen A. Elias	
(Use Several Sheets if Necessary)	Filing Date HEREWITH	Group UNASSIGNED

	C10		tion of Computerized Analysis of Nuclear Images	
n		and Multivariate Analysis to	the Understanding of the Effects of	
		Antineoplastic Agents and T	heir Mechanism of Action", Meth. Find. Exp.	
1		Clin. Pharmacol, 15(2): 113-		
·200	C11	Teri Adams, et al., "Cell Pat	terning on Glass and Polymeric Substrates", U.S.	
		·	on No.: 60/127,138,119, Filed June 7, 1999, 21	
		Pages.		
Rubas	Ç12		etermine Epithelial Transport and Bioactivity of	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	EIGH	Oral Drug Candidates in Vita	ro," Pharmaceutical Research, Vol. 13, No. 1,	
LRG		Pages 23-27, 1996		
V	C13	Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C, "Regulation		
W/		Collagenase-3 Expression in	Human Breast Carcinomas in Mediated by	
18/		Stromal-Epithelial Cell Inter	actions", Cancer Res 1997 Nov 1;57 (21):4882-8,	
N.		Abstract		
	C14	Pauwels et al., "Combination	n of Computerized Morphonuclear and	
1 1215		Multivariate Analyses to Ch	aracterize In Vitro the Antineoplastic Effect of	
17			macol. and Toxicol. Methods, 33(1): 34-45 (1995).	
	C15	Weinstein et al., "An Information-Intensive Approach to the Molecular Pharmacology of Cancer", Science. 275: 43-349 (January 17, 1997).		
100				
12				
Examiner	110	$\mathcal{C}$	Date Considered	
1 -	WS.	Druss	140ctole 2007	

Examiner: Unitial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.